Is EGRX or PYRGF more profitable?

Eagle Pharmaceuticals has a net margin of 0.00% compared to PyroGenesis Canada's net margin of -115.14%. Company Net Margins Return on Equity Return on Assets Eagle Pharmaceuticals N/A N/A N/A PyroGenesis Canada -115.14% N/A -60.81%

Do analysts prefer UG or EGRX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score United-Guardian 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Eagle Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Do analysts recommend EGRX or ACTU?

Actuate Therapeutics has a consensus price target of $10.50, suggesting a potential upside of 733.33%. Given Actuate Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Actuate Therapeutics is more favorable than Eagle Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Eagle Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Actuate Therapeutics 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33

Is EGRX or ACTU more profitable?

Eagle Pharmaceuticals' return on equity of 0.00% beat Actuate Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Eagle Pharmaceuticals N/A N/A N/A Actuate Therapeutics N/A -346.19% -178.40%

Do analysts prefer EGRX or NNVC?

NanoViricides has a consensus price target of $6.00, suggesting a potential upside of 476.92%. Given NanoViricides' stronger consensus rating and higher probable upside, analysts plainly believe NanoViricides is more favorable than Eagle Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Eagle Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 NanoViricides 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00

Is EGRX or NNVC more profitable?

Eagle Pharmaceuticals' return on equity of 0.00% beat NanoViricides' return on equity. Company Net Margins Return on Equity Return on Assets Eagle Pharmaceuticals N/A N/A N/A NanoViricides N/A -87.90% -78.69%

Do analysts rate TAOX or EGRX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Synaptogenix 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Eagle Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Eagle Pharmaceuticals (EGRX) Competitors

$0.75 0.00 (0.00%)

As of 09/8/2026

Compare

EGRX vs. PYRGF, UG, ACTU, NNVC, and TAOX

Should you buy Eagle Pharmaceuticals stock or one of its competitors? Eagle Pharmaceuticals's main competitors and comparable companies include PyroGenesis Canada (PYRGF), United-Guardian (UG), Actuate Therapeutics (ACTU), NanoViricides (NNVC), and Synaptogenix (TAOX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Eagle Pharmaceuticals compare to PyroGenesis Canada?

Eagle Pharmaceuticals (NASDAQ:EGRX) and PyroGenesis Canada (NASDAQ:PYRGF) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, risk, analyst recommendations, dividends, valuation, earnings and profitability.

Eagle Pharmaceuticals has a net margin of 0.00% compared to PyroGenesis Canada's net margin of -115.14%.

Company	Net Margins	Return on Equity	Return on Assets
Eagle Pharmaceuticals	N/A	N/A	N/A
PyroGenesis Canada	-115.14%	N/A	-60.81%

85.4% of Eagle Pharmaceuticals shares are owned by institutional investors. Comparatively, 0.0% of PyroGenesis Canada shares are owned by institutional investors. 28.9% of Eagle Pharmaceuticals shares are owned by insiders. Comparatively, 47.7% of PyroGenesis Canada shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Eagle Pharmaceuticals has higher revenue and earnings than PyroGenesis Canada. PyroGenesis Canada is trading at a lower price-to-earnings ratio than Eagle Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eagle Pharmaceuticals	$257.55M	0.04	$35.64M	$1.18	0.64
PyroGenesis Canada	$9.14M	3.52	-$21.12M	-$0.04	N/A

In the previous week, Eagle Pharmaceuticals' average media sentiment score of 0.67 beat PyroGenesis Canada's score of 0.00 indicating that Eagle Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Eagle Pharmaceuticals	Positive
PyroGenesis Canada	Neutral

Eagle Pharmaceuticals has a beta of 0.83, indicating that its stock price is 17% less volatile than the broader market. Comparatively, PyroGenesis Canada has a beta of 0.27, indicating that its stock price is 73% less volatile than the broader market.

Summary

Eagle Pharmaceuticals beats PyroGenesis Canada on 9 of the 11 factors compared between the two stocks.

How does Eagle Pharmaceuticals compare to United-Guardian?

United-Guardian (NASDAQ:UG) and Eagle Pharmaceuticals (NASDAQ:EGRX) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, valuation, analyst recommendations, risk, media sentiment, institutional ownership, earnings and profitability.

United-Guardian has a net margin of 22.01% compared to Eagle Pharmaceuticals' net margin of 0.00%. United-Guardian's return on equity of 22.24% beat Eagle Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
United-Guardian	22.01%	22.24%	19.12%
Eagle Pharmaceuticals	N/A	N/A	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
United-Guardian	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Eagle Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Eagle Pharmaceuticals has higher revenue and earnings than United-Guardian. Eagle Pharmaceuticals is trading at a lower price-to-earnings ratio than United-Guardian, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
United-Guardian	$10.55M	3.08	$2.11M	$0.54	13.11
Eagle Pharmaceuticals	$257.55M	0.04	$35.64M	$1.18	0.64

23.2% of United-Guardian shares are held by institutional investors. Comparatively, 85.4% of Eagle Pharmaceuticals shares are held by institutional investors. 29.0% of United-Guardian shares are held by insiders. Comparatively, 28.9% of Eagle Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

United-Guardian has a beta of 0.96, indicating that its stock price is 4% less volatile than the broader market. Comparatively, Eagle Pharmaceuticals has a beta of 0.83, indicating that its stock price is 17% less volatile than the broader market.

In the previous week, Eagle Pharmaceuticals' average media sentiment score of 0.67 beat United-Guardian's score of 0.00 indicating that Eagle Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
United-Guardian	Neutral
Eagle Pharmaceuticals	Positive

Summary

United-Guardian beats Eagle Pharmaceuticals on 8 of the 13 factors compared between the two stocks.

How does Eagle Pharmaceuticals compare to Actuate Therapeutics?

Eagle Pharmaceuticals (NASDAQ:EGRX) and Actuate Therapeutics (NASDAQ:ACTU) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, dividends, risk, institutional ownership, earnings, media sentiment, analyst recommendations and profitability.

Eagle Pharmaceuticals' return on equity of 0.00% beat Actuate Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eagle Pharmaceuticals	N/A	N/A	N/A
Actuate Therapeutics	N/A	-346.19%	-178.40%

Actuate Therapeutics has a consensus price target of $10.50, suggesting a potential upside of 733.33%. Given Actuate Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Actuate Therapeutics is more favorable than Eagle Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eagle Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Actuate Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

In the previous week, Actuate Therapeutics had 3 more articles in the media than Eagle Pharmaceuticals. MarketBeat recorded 3 mentions for Actuate Therapeutics and 0 mentions for Eagle Pharmaceuticals. Eagle Pharmaceuticals' average media sentiment score of 0.67 beat Actuate Therapeutics' score of 0.34 indicating that Eagle Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Eagle Pharmaceuticals	Positive
Actuate Therapeutics	Neutral

Eagle Pharmaceuticals has a beta of 0.83, indicating that its share price is 17% less volatile than the broader market. Comparatively, Actuate Therapeutics has a beta of 0.95, indicating that its share price is 5% less volatile than the broader market.

85.4% of Eagle Pharmaceuticals shares are held by institutional investors. 28.9% of Eagle Pharmaceuticals shares are held by insiders. Comparatively, 58.0% of Actuate Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Eagle Pharmaceuticals has higher revenue and earnings than Actuate Therapeutics. Actuate Therapeutics is trading at a lower price-to-earnings ratio than Eagle Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eagle Pharmaceuticals	$257.55M	0.04	$35.64M	$1.18	0.64
Actuate Therapeutics	N/A	N/A	-$22.23M	-$0.87	N/A

Summary

Eagle Pharmaceuticals beats Actuate Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Eagle Pharmaceuticals compare to NanoViricides?

Eagle Pharmaceuticals (NASDAQ:EGRX) and NanoViricides (NYSE:NNVC) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, risk, profitability, dividends, analyst recommendations, earnings, institutional ownership and valuation.

Eagle Pharmaceuticals has higher revenue and earnings than NanoViricides. NanoViricides is trading at a lower price-to-earnings ratio than Eagle Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eagle Pharmaceuticals	$257.55M	0.04	$35.64M	$1.18	0.64
NanoViricides	N/A	N/A	-$8.29M	-$0.43	N/A

Eagle Pharmaceuticals has a beta of 0.83, meaning that its stock price is 17% less volatile than the broader market. Comparatively, NanoViricides has a beta of 1.66, meaning that its stock price is 66% more volatile than the broader market.

NanoViricides has a consensus price target of $6.00, suggesting a potential upside of 476.92%. Given NanoViricides' stronger consensus rating and higher probable upside, analysts plainly believe NanoViricides is more favorable than Eagle Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eagle Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
NanoViricides	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00

Eagle Pharmaceuticals' return on equity of 0.00% beat NanoViricides' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eagle Pharmaceuticals	N/A	N/A	N/A
NanoViricides	N/A	-87.90%	-78.69%

In the previous week, NanoViricides had 2 more articles in the media than Eagle Pharmaceuticals. MarketBeat recorded 2 mentions for NanoViricides and 0 mentions for Eagle Pharmaceuticals. Eagle Pharmaceuticals' average media sentiment score of 0.67 beat NanoViricides' score of 0.38 indicating that Eagle Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Eagle Pharmaceuticals	Positive
NanoViricides	Neutral

85.4% of Eagle Pharmaceuticals shares are owned by institutional investors. Comparatively, 10.3% of NanoViricides shares are owned by institutional investors. 28.9% of Eagle Pharmaceuticals shares are owned by company insiders. Comparatively, 3.6% of NanoViricides shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Eagle Pharmaceuticals beats NanoViricides on 9 of the 14 factors compared between the two stocks.

How does Eagle Pharmaceuticals compare to Synaptogenix?

Synaptogenix (NASDAQ:TAOX) and Eagle Pharmaceuticals (NASDAQ:EGRX) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, dividends, media sentiment, profitability, earnings and risk.

Eagle Pharmaceuticals has higher revenue and earnings than Synaptogenix. Synaptogenix is trading at a lower price-to-earnings ratio than Eagle Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Synaptogenix	$300K	100.48	-$28.74M	-$3.85	N/A
Eagle Pharmaceuticals	$257.55M	0.04	$35.64M	$1.18	0.64

10.3% of Synaptogenix shares are held by institutional investors. Comparatively, 85.4% of Eagle Pharmaceuticals shares are held by institutional investors. 2.7% of Synaptogenix shares are held by company insiders. Comparatively, 28.9% of Eagle Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Synaptogenix	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Eagle Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Synaptogenix has a beta of 1.49, indicating that its share price is 49% more volatile than the broader market. Comparatively, Eagle Pharmaceuticals has a beta of 0.83, indicating that its share price is 17% less volatile than the broader market.

In the previous week, Eagle Pharmaceuticals' average media sentiment score of 0.67 beat Synaptogenix's score of 0.00 indicating that Eagle Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Synaptogenix	Neutral
Eagle Pharmaceuticals	Positive

Eagle Pharmaceuticals has a net margin of 0.00% compared to Synaptogenix's net margin of -2,153.97%. Eagle Pharmaceuticals' return on equity of 0.00% beat Synaptogenix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Synaptogenix	-2,153.97%	-128.51%	-97.54%
Eagle Pharmaceuticals	N/A	N/A	N/A

Summary

Eagle Pharmaceuticals beats Synaptogenix on 10 of the 13 factors compared between the two stocks.

Get Eagle Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding EGRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

EGRX vs. The Competition

Export

Metric	Eagle Pharmaceuticals	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$9.74M	$12.48B	$7.22B	$12.88B
Dividend Yield	N/A	2.61%	2.55%	9.95%
P/E Ratio	0.64	794.76	271.78	25.29
Price / Sales	0.04	956.01	713.06	118.17
Price / Cash	0.40	91.31	77.55	52.32
Price / Book	N/A	10.60	10.51	6.26
Net Income	$35.64M	$2.81B	$3.48B	$357.86M
7 Day Performance	N/A	-1.88%	-1.16%	-0.59%
1 Month Performance	N/A	3.14%	2.02%	-1.07%
1 Year Performance	-76.64%	5.55%	21.91%	11.31%

Eagle Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
EGRX Eagle Pharmaceuticals	N/A	$0.75 flat	N/A	N/A	$9.74M	$257.55M	0.64	100
PYRGF PyroGenesis Canada	N/A	$0.15 -2.3%	N/A	-19.2%	$34.29M	$9.14M	N/A	90	High Trading Volume
UG United-Guardian	1.2467 of 5 stars	$7.13 0.0%	N/A	-16.7%	$32.89M	$11.21M	13.26	20
ACTU Actuate Therapeutics	2.4615 of 5 stars	$1.33 -13.9%	$10.50 +691.9%	-85.2%	$32.20M	N/A	N/A	10	News Coverage Positive News Gap Up
NNVC NanoViricides	2.0124 of 5 stars	$1.17 -3.7%	$6.00 +415.0%	-28.8%	$29.74M	N/A	N/A	20	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:EGRX) was last updated on 9/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Eagle Pharmaceuticals (EGRX) Competitors

EGRX vs. PYRGF, UG, ACTU, NNVC, and TAOX

How does Eagle Pharmaceuticals compare to PyroGenesis Canada?

Summary

How does Eagle Pharmaceuticals compare to United-Guardian?

Summary

How does Eagle Pharmaceuticals compare to Actuate Therapeutics?

Summary

How does Eagle Pharmaceuticals compare to NanoViricides?

Summary

How does Eagle Pharmaceuticals compare to Synaptogenix?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EGRX vs. The Competition

Eagle Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Eagle Pharmaceuticals (EGRX) Competitors

EGRX vs. PYRGF, UG, ACTU, NNVC, and TAOX

How does Eagle Pharmaceuticals compare to PyroGenesis Canada?

Is EGRX or PYRGF more profitable?

Do insiders & institutionals hold more shares of EGRX or PYRGF?

Which has preferable valuation & earnings, EGRX or PYRGF?

Does the media refer more to EGRX or PYRGF?

Which has more volatility & risk, EGRX or PYRGF?

Summary

How does Eagle Pharmaceuticals compare to United-Guardian?

Is UG or EGRX more profitable?

Do analysts prefer UG or EGRX?

Which has higher valuation and earnings, UG or EGRX?

Do insiders & institutionals hold more shares of UG or EGRX?

Which has more volatility & risk, UG or EGRX?

Does the media prefer UG or EGRX?

Summary

How does Eagle Pharmaceuticals compare to Actuate Therapeutics?

Is EGRX or ACTU more profitable?

Do analysts recommend EGRX or ACTU?

Does the media favor EGRX or ACTU?

Which has more volatility & risk, EGRX or ACTU?

Do insiders and institutionals hold more shares of EGRX or ACTU?

Which has stronger earnings and valuation, EGRX or ACTU?

Summary

How does Eagle Pharmaceuticals compare to NanoViricides?

Which has preferable earnings and valuation, EGRX or NNVC?

Which has more risk and volatility, EGRX or NNVC?

Do analysts prefer EGRX or NNVC?

Is EGRX or NNVC more profitable?

Does the media favor EGRX or NNVC?

Do institutionals and insiders hold more shares of EGRX or NNVC?

Summary

How does Eagle Pharmaceuticals compare to Synaptogenix?

Which has better valuation and earnings, TAOX or EGRX?

Do institutionals and insiders have more ownership in TAOX or EGRX?

Do analysts rate TAOX or EGRX?

Which has more risk and volatility, TAOX or EGRX?

Does the media refer more to TAOX or EGRX?

Is TAOX or EGRX more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EGRX vs. The Competition

Eagle Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools